市场调查报告书
商品编码
1276821
真皮填充剂全球市场规模、份额和行业趋势分析报告:按类型、产品、最终用途、应用、地区划分的展望和预测,2023-2029 年Global Dermal Fillers Market Size, Share & Industry Trends Analysis Report By Type, By Product, By End-use (MedSpa, Cosmetic Surgery Clinics and Hospitals), By Application, By Regional Outlook and Forecast, 2023 - 2029 |
真皮填充剂市场规模预计将在 2029 年达到 103 亿美元,在预测期内以 8.1% 的复合年增长率增长。
HA 和胶原蛋白是可生物降解的临时真皮填充剂的两个示例,使用寿命为 4-9 个月。 不满和潜在的有害影响都是暂时的。
因此,临时填充剂始终被用作一线治疗,有利于后续使用的长效填充剂。 除了常见的面部皱纹,永久性填充剂主要用于治疗皮肤深层皱纹和摺痕。 它被认为是面部年轻化的最佳选择,尤其是在 HIV 脂肪代谢障碍中。 PMMA 因其有效、持久和安全的效果而被广泛使用。
COVID-19 影响分析
由于 COVID-19 封锁,医用化妆品行业经历了供应链延误,包括进出口限制、航班取消、减产和供应线中断。 此外,包括透明质酸和肉毒桿菌毒素在内的非手术治疗减少了总使用量。 因此,大流行期间产品需求的下降进一步影响了市场的扩张。 真皮填充剂市场受到 COVID-19 大流行的影响。 然而,在 COVID-19 病例下降后放宽限制将有助于真皮填充剂市场从大流行期间的损失中恢復过来。
市场增长因素
注射填充剂在男性中越来越受欢迎
这个市场中最广泛的趋势之一是几乎所有人群都表现出对微创或非侵入性手术的倾向或倾向。 这对于追求审美美感的男士来说尤为重要。 例如,越来越多的男性发现地心引力和衰老会对他们的面部外观产生负面影响。 结果,男性选择了面部填充手术,因为他们成功地逆转了面部的早期重力老化。 它还具有不需要停机即可恢復的额外好处。
微创方法的增加
在微创手术中,手术是使用范围和专门的观察仪器进行的。 减少体积、形状和不需要的脂肪,同时关注皱纹和细纹等面部异常。 微创技术越来越受欢迎,因为它们几乎没有严重副作用的风险,需要的切口很少,而且恢復速度很快。 对用于减少皱纹、收紧皮肤、面部轮廓和年轻化的基于能量的微创手术的需求是巨大的。 预计这些因素将推动市场的扩张。
市场製约因素
与真皮填充剂相关的高成本
儘管化妆品应用范围广泛,但预计在预测期内市场增长将放缓。 市场增长放缓的主要障碍之一是这些产品的高价标籤。 Derma filler 价格可能因许多变量而异,包括手术类型、从业者的经验和资格,以及完成手术或治疗所需的时间和精力。 因此,与真皮填充剂相关的高成本预计会阻碍市场增长。
产品展望
真皮填充剂市场按产品细分为透明质酸、羟基磷灰石钙、聚乳酸 (PLLA)、聚甲基丙烯酸甲酯微球等。 在 2022 年的真皮填充剂市场中,羟基磷灰石钙细分市场赢得了很大的收入份额。 这种增长归功于其安全特性。 主要参与者在该市场推出新产品也促进了该细分市场的扩张。 氢氧化钙磷灰石 (CaHA) 会随着时间的推移刺激胶原蛋白,是可注射真皮填充剂中的活性成分。 它可以提升软组织下垂,减少下眼睑下垂,并在不治疗泪囊周围区域的情况下减少泪囊。
按类型划分的前景
真皮填充剂市场按类型分为可生物降解和不可生物降解。 到 2022 年,可生物降解部分将在真皮填充剂市场占据最大的收入份额。 这是因为与不可生物降解的类别相比,该细分市场的产品选择更多,而可生物降解的产品在化妆品中的应用范围更广。 该细分市场的增长预计也将受到高产品安全性和稳健监管批准的推动。
使用展望
根据应用,真皮填充剂市场可细分为皱纹矫正、面部轮廓、疤痕治疗、丰唇等。 到 2022 年,真皮填充剂市场将由唇部提升部分主导,收入份额显着。 这是由于大量的唇处理。 微创手术的出现推动了对唇部美容的需求不断增加,预计这一类别将受到推动。 唇部填充物是一种美容疗法,可以增加嘴唇的丰盈度。
结束使用 Outlook
真皮填充剂市场根据最终用户细分为水疗中心、整容手术诊所和医院。 2022 年,医院部门在真皮填充剂市场的增长率令人鼓舞。 这是由于在医院进行的面部注射等整容手术的普遍存在。 此外,高科技设备、员工和其他设施的存在增加了信任医院进行各种填充手术的患者的知名度,从而进一步为该细分市场提供了增长机会。
区域展望
按地区分析了北美、欧洲、亚太地区和 LAMEA 的真皮填充剂市场。 到 2022 年,北美地区将占据真皮填充剂市场的最高收入份额。 这是由于该地区永恆之美的增长趋势、其在男性中的日益流行以及对非手术整容手术的日益增长的需求。 在北美,人们非常在意自己的外表和审美标准。 这导致对真皮填充剂的需求不断增长,以改善面部特征和减少衰老迹象。
The Global Dermal Fillers Market size is expected to reach $10.3 billion by 2029, rising at a market growth of 8.1% CAGR during the forecast period.
The purpose of dermal fillers is to impart volume and fullness to the skin through injection. A mineral-like substance found in bones called calcium hydroxylapatite, polyalkylimide, hyaluronic acid, polylactic acid, and polymethyl-methacrylate microspheres is among the ingredients utilized in dermal fillers (PMMA).
In addition, the deep dermis, depth of implantation (superficial midterms and upper and subcutaneous levels), the longevity of correction (temporary and permanent), allergenicity, the agent's composition (allografts, semi/fully synthetic, xenografts, or autologous), and stimulatory behavior (physiologic processes of endogenous tissue proliferation) versus replacement fillers are some of the criteria that can be used to classify dermal fillers (space-replacing effect).
HA and collagen are two examples of temporary dermal fillers that are biodegradable and have a lifespan of between four and nine months. Both dissatisfaction and the possibility of detrimental effects are temporary occurrences.
Therefore, in order to save long-lasting fillers for subsequent patient visits, temporary fillers are always employed as the initial line of treatment. Permanent fillers are mostly utilized to treat deep skin wrinkles and furrows that go beyond the scope of typical face creases. They are considered a top choice for face rejuvenation, particularly in HIV lipodystrophy. PMMA is generally employed for effects that are effective, long-lasting, and safe.
COVID-19 Impact Analysis
The medical cosmetics industry experienced supply chain delays due to the COVID-19-imposed lockdowns, which included restrictions on import and export, flight cancellations, decreased production, and disrupted supply lines. Moreover, nonsurgical procedures involving hyaluronic acid and botulinum toxin saw a decline in total usage. Thus, the drop in product demand during the pandemic further impacted the market expansion. The market for dermal fillers has been affected by the COVID-19 pandemic. However, the market for dermal fillers will be driven by the relaxation of regulatory regulations after the decreasing cases of COVID-19, thereby aiding the market to recover after the losses during the pandemic.
Market Growth Factors
The rising popularity of injectable fillers among men
One of the most pervasive trends in the market is that practically all demographic groups have demonstrated a desire or predisposition for these minimally invasive or non-invasive procedures. For the male demographic, who are increasingly using these operations to improve their appearance, this is especially important. For instance, a growing number of men are discovering that gravity and aging can have a detrimental effect on the way their facial features look. As a result, males choose facial filler procedures due to their success in reversing the early gravitational aging of the face. Also, it offers the extra benefit of requiring no downtime for recuperation.
Increasing use of less invasive methods
A scope for seeing and surgical instruments with specialized equipment are used in minimally invasive surgery. It reduces volume, shape, and undesirable fat while concentrating on the abnormalities of the face, such as wrinkles and fine lines. Minimally invasive techniques are becoming more popular because they have almost no risk of significant adverse outcomes and need few or no cuts with quick recovery. There is a huge demand for energy-based, minimally invasive procedures for wrinkle reduction, skin tightening, face contouring, and rejuvenation. These mentioned factors are expected to propel the market's expansion.
Market Restraining Factors
The high cost associated with dermal fillers
The growth of the market is anticipated to be constrained throughout the forecast period, despite the wide range of aesthetic applications. One of the main barriers hindering the slowdown in the expansion of the market is the high price tag attached to these products. Dermal filler prices can vary depending on a variety of variables, including the type of procedure performed, the experience and credentials of the practitioner, and the amount of time and effort necessary to complete the surgery or treatment. Thus, the high cost associated with dermal fillers is expected to hinder the market's growth.
Product Outlook
Based on product, the dermal fillers market is segmented into hyaluronic acid, calcium hydroxylapatite, polylactic acid (PLLA), polymethyl-methacrylate microspheres and others. The calcium hydroxylapatite segment acquired a significant revenue share in the dermal fillers market in 2022. The growth is attributed to its safety characteristics. Key players' launches of new goods in this market also contribute to the segment's expansion. Calcium hydroxylapatite (CaHA), which stimulates collagen over time, is an active constituent in the injectable dermal filler. Without treating the area around the tear trough, one can lift sagging soft tissues, lessen lower eyelid lag, and decrease the tear trough.
Type Outlook
On the basis of type, the dermal fillers market is divided into biodegradable and non-biodegradable. The biodegradable segment witnessed the largest revenue share in the dermal fillers market in 2022. This is due to the presence of more product options in this segment than in the non-biodegradable category and because biodegradable products have more varied aesthetic uses. The segment's expansion is also anticipated to be aided by the goods' higher level of safety and solid regulatory approval.
Application Outlook
By application, the dermal fillers market is classified into wrinkle correction, facial contouring, scar treatment, lip enhancement and others. The lip enhancement segment garnered a prominent revenue share in the dermal fillers market in 2022. This is due to the strong volume of lip procedures. The category is anticipated to be driven by the increased demand for cosmetic enhancements of the lips, fueled by the advent of minimally invasive procedures. Lip fillers are a cosmetic treatment that can enhance the volume of lips.
End-Use Outlook
Based on the end-use, the dermal fillers market is bifurcated into MedSpa, cosmetic surgery clinics and hospitals. The hospital segment recorded a promising growth rate in the dermal fillers market in 2022. This is owing to the widespread use of aesthetic procedures like face injectables carried out in hospitals. In addition, the presence of high-tech equipment, staff and other facilities increased their popularity among patients who trust hospitals for various types of filler surgeries, and thus further providing growth opportunities for the segment.
Regional Outlook
Region-wise, the dermal fillers market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generated the highest revenue share in the dermal fillers market in 2022. This is due to the region's developing trend of ageless beauty, increased popularity among men, and rising desire for non-surgical aesthetic procedures. In North America, people care a lot about their looks and beauty standards. Due to this, there is a significant demand for dermal fillers to improve face characteristics and lessen aging symptoms.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bioplus Co. Ltd, Bioxis pharmaceuticals, Suneva Medical, Inc., Galderma S.A., Allergan PLC (AbbVie, Inc.), Sinclair Pharma Ltd. (Huadong Medicine Co., Ltd.), Revance Therapeutics, Inc., Medytox Inc., Merz Pharma GmbH & Co. KGaA and Prollenium Medical Technologies Inc.
Strategies Deployed in Dermal Fillers Market
Mar-2023: Galderma revealed FACE by Galderma, an aesthetic visualization tool that enables aesthetic professionals and patients to visualize injectable treatment results. The FACE by Galderma would enable aesthetic professionals to identify and tailor an individualized treatment plan to meet the needs and aesthetic goals of each patient.
Oct-2022: Prollenium Medical Technologies took over SoftFil, the cosmetic aesthetic leader. This acquisition results in creating synergies between the two brands and further expands and strengthens its presence in international markets.
Sep-2022: Revance Therapeutics received US FDA clearance for its DAXXIFY (DaxibotulinumtoxinA-lanm). The approved product provides temporary improvement of moderate to severe frown lines in adults. 2020-Jan: Revance entered into an agreement with Teoxane SA, a Swiss developer of aesthetic medicine. The agreement includes Revance acting as an exclusive distributor for Teoxane's dermal filler products.
Feb-2022: Merz Aesthetics released Radiesse® (+) Lidocaine injectable implant for soft tissue augmentation, enhancing mild to severe jawline contour loss in adults over 21. The launch is aimed at meeting the demand of patients seeking a more defined and contoured jawline.
Jan-2022: Galderma completed the acquisition of ALASTIN Skincare®, Inc, which provides a collection of cutting-edge products for optimal procedure results and daily skincare regimens. The acquisition would enhance the dermatology platform of Galderma with a comprehensive collection of scientifically proven products for daily skincare regimens and post-operative care and reinforce the company's commitment to being aesthetic professionals' partner of choice.
Sep-2021: Galderma joined hands with Sofregen Medical, Inc., a medical device company that uses silk protein for tissue building and regeneration. This collaboration would enhance Galderma's capability to build on decades of biostimulation and hyaluronic acid (HA) filler innovation.
Jun-2021: Medytox received approval from the Taiwan Food and Drug Administration for marketing its botulinum toxin Meditoxin in Taiwan. The Approval would allow the company to expand its business in Southeast Asian countries.
Feb-2021: Sinclair Pharma unveiled Lanluma V, for the face and hands and Lanluma X for the rest of the body. The new products are designed to stimulate collagenases to improve the skin's inner structure and shape, reshape and enhance the fullness of different areas of the body, and reduce cellulite.
Oct-2020: Allergan took over Luminera's dermal filler business. The addition of Luminera's entire dermal portfolio and R&D pipeline improves the acquiring company's dermal filler offerings. Further, Luminera's assets perfectly complement Allergan's JUVEDERM® filler franchise.
Sep-2020: Suneva Medical, Inc. entered into a partnership with Neauvia North America, a subsidiary of Neauvia, a global aesthetics brand. Through this partnership, the company would provide Neauvia North America's Plasma IQ throughout North America. Plasma IQ complements Suneva Medical's portfolio of facial regenerative aesthetics products that would enable the company to offer proven and validated solutions for aesthetic providers and their patients.
Jun-2020: Galderma launched Restylane Kysse, a newly approved lip filler. The Restylane Kysse is a hyaluronic acid (HA) filler that is proven to last for up to 1 year. The product is approved for lip augmentation and the correction of wrinkles around the upper lips.
Jan-2020: Revance entered into an agreement with Teoxane SA, a Swiss developer of aesthetic medicine. The agreement includes Revance acting as an exclusive distributor for Teoxane's dermal filler products.
Sep-2019: Merz expanded its geographical footprint by opening a manufacturing site in Dessau. The new production plant would cater to the evolving demand for its Belotero dermal fillers. Moreover, the location of the new facility to secure the international supply of its medical aesthetics products.
Apr-2019: Merz revealed Belotero Revive, a dermal filler product that contains a combination of hyaluronic acid (HA) and glycerol. The Belotero® Revive is designed to enhance hydration, elasticity, and firmness of the skin and to address the appearance of fine lines.
Market Segments covered in the Report:
By Type
By Product
By End-use
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures